Patents by Inventor Cynthia Bamdad

Cynthia Bamdad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230242678
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Application
    Filed: June 27, 2021
    Publication date: August 3, 2023
    Inventors: Cynthia BAMDAD, Benoit SMAGGHE
  • Publication number: 20230242874
    Abstract: The present application discloses a method of producing dopaminergic neurons from human stem cells by adding or increasing concentration of vitamin into neuro basal media at approximately Day 20+/?3 of a protocol for differentiating pluripotent stem cells into dopaminergic neurons.
    Type: Application
    Filed: June 28, 2021
    Publication date: August 3, 2023
    Inventors: Cynthia BAMDAD, Kevin R. YI, Scott T. MOE, Thomas JEON
  • Patent number: 11702483
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: July 18, 2023
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Publication number: 20230183373
    Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof.
    Type: Application
    Filed: August 4, 2022
    Publication date: June 15, 2023
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Patent number: 11591565
    Abstract: The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: February 28, 2023
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Publication number: 20230049461
    Abstract: The present application discloses a method for generating less mature cells from starting cells including inducing the starting cells to revert to a less mature state including increasing the amount of an NME family member whose multimerization state is the biologically active state or decreasing the relative amount of an NME family member whose multimerization state is the biologically inactive state.
    Type: Application
    Filed: September 27, 2022
    Publication date: February 16, 2023
    Inventor: Cynthia BAMDAD
  • Patent number: 11560435
    Abstract: The present describes monoclonal antibody to MUC1*.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: January 24, 2023
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Sanjeev Mahanta
  • Publication number: 20220289865
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Application
    Filed: April 12, 2022
    Publication date: September 15, 2022
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Publication number: 20220259324
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Application
    Filed: August 3, 2021
    Publication date: August 18, 2022
    Applicant: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Publication number: 20220252604
    Abstract: The present application describes a method of culturing, expanding or growing stem or stem-like cells or induced pluripotent stem cells on a surface, including attaching the cells to the surface through a ligand that binds to the surface and the cells.
    Type: Application
    Filed: June 21, 2021
    Publication date: August 11, 2022
    Inventor: Cynthia Bamdad
  • Publication number: 20220242823
    Abstract: The present application discloses a method for identifying an agent for the treatment or prevention of cancer or metastatic cancer comprising the steps of contacting stem cell with a potential agent, and identifying an agent that induces differentiation, or inhibits stem cell pluripotency or growth of the stem cell, wherein such agent is determined to be an anti-cancer agent.
    Type: Application
    Filed: October 28, 2021
    Publication date: August 4, 2022
    Inventors: Cynthia BAMDAD, Scott MOE
  • Publication number: 20220193270
    Abstract: The present application discloses a method of testing for efficacy of a potential drug agent against cancerous cells in a mammal, including generating the cancer cells in a mammal; contacting the cancer cells with a potential drug agent by administering the potential drug agent to the mammal; and measuring effect of the potential drug agent on the cancer cells, wherein reduction of number of cancer cells in the mammal is indicative of efficaciousness of the potential drug agent against cancerous cells.
    Type: Application
    Filed: October 4, 2021
    Publication date: June 23, 2022
    Inventor: Cynthia BAMDAD
  • Publication number: 20220184120
    Abstract: The present application discloses an antibody, or fragment thereof, for the diagnosis, treatment or prevention of cancers wherein the antibody specifically binds to the PSMGFR peptide (SEQ ID NO:2) or a fragment thereof of the peptide.
    Type: Application
    Filed: July 12, 2021
    Publication date: June 16, 2022
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Publication number: 20220089779
    Abstract: The present application discloses inhibitors of NME family of proteins.
    Type: Application
    Filed: May 3, 2021
    Publication date: March 24, 2022
    Applicant: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia BAMDAD, Benoit Smagghe
  • Publication number: 20210308213
    Abstract: The present application discloses a method for converting a cell to naïve state stem cells comprising contacting the cell to be converted with an NME protein.
    Type: Application
    Filed: June 21, 2021
    Publication date: October 7, 2021
    Inventors: Cynthia Bamdad, Benoit Smagghe, Mark G. Carter
  • Publication number: 20210299109
    Abstract: The present application discloses a method for identifying an agent for the treatment or prevention of cancer or metastatic cancer comprising the steps of contacting stem cell with a potential agent, and identifying an agent that induces differentiation, or inhibits stem cell pluripotency or growth of the stem cell, wherein such agent is determined to be an anti-cancer agent.
    Type: Application
    Filed: December 19, 2018
    Publication date: September 30, 2021
    Inventors: Cynthia BAMDAD, Scott MOE
  • Publication number: 20210087143
    Abstract: The present application discloses a method for identifying an agent for the treatment or prevention of cancer or metastatic cancer comprising the steps of contacting stem cell with a potential agent, and identifying an agent that induces differentiation, or inhibits stem cell pluripotency or growth of the stem cell, wherein such agent is determined to be an anti-cancer agent.
    Type: Application
    Filed: March 29, 2018
    Publication date: March 25, 2021
    Inventors: Cynthia BAMDAD, Scott MOE
  • Publication number: 20210054358
    Abstract: The present application discloses a method for inducing cells to gain characteristics of naïve stem cell state comprising culturing the cells in the presence of a MUC1* activator.
    Type: Application
    Filed: June 25, 2020
    Publication date: February 25, 2021
    Applicant: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventor: Cynthia Bamdad
  • Publication number: 20200405832
    Abstract: The present application discloses a composition comprising a MUC1* extra cellular domain peptide attached to a surface and an immune cell that bears a receptor that binds to the peptide.
    Type: Application
    Filed: March 11, 2019
    Publication date: December 31, 2020
    Inventors: Cynthia BAMDAD, Nelson GLENNIE
  • Publication number: 20200407462
    Abstract: The present application discloses a method of determining suitability of treating a patient suffering from cancer or metastasis of cancer characterized by aberrant expression of MUC1, with a MUC1* targeting therapeutic.
    Type: Application
    Filed: February 26, 2019
    Publication date: December 31, 2020
    Inventor: Cynthia BAMDAD